ArticleNature2025
Humoral determinants of checkpoint immunotherapy.
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.British journal of cancer · 2026Article
- Clinical and pathological significance of serum anti-PD-1 autoantibodies in acute-onset and chronic autoimmune hepatitis.Hepatology international · 2026Article
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.iScience · 2026Article
- Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy.Nature reviews. Immunology · 2026Review
- The evolution of display technologies for antibody drug discovery.Trends in biotechnology · 2026Review
- Humoral contributions to checkpoint blockade therapy.Journal for immunotherapy of cancer · 2026Article
- High prevalence of CNS-directed autoantibodies in patients with schizophrenia.bioRxiv : the preprint server for biology · 2026Article
- Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.Nature medicine · 2026Article
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells.Frontiers in immunology · 2026Article
- Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025Article
- Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities.Journal of hematology & oncology · 2025Review
- Machine learning-based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Although the role of cellular immunity in checkpoint immunotherapy (CPI) for cancer is well established
Indexed as
Identifiers
40702172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.